Sunitinib 50mg Capsule
Prescription Required
Marketed By
Arechar HealthCare
Pack of
28 capsules in Bottle
Salt Composition
Sunitinib
Storage
Keep in cold place
₹3250₹7150
54.55% Off
Inclusive of all taxes
1
Sunitinib 50mg Capsule
Delivering To: —
All Substitutes
Overview
Sunitinib 50 mg Capsule is a cancer-fighting medicine as it belongs to the antineoplastic agents group of medicine. The doctor prescribes this medicine to treat Gastrointestinal stromal cancer, kidney cancer, and pancreatic neuroendocrine tumors. Sunitinib 50mg Capsule is a small molecule that inhibits the action of multiple Receptor Tyrosine Kinase (RTKs), some of which are connected to tumor growth, pathological angiogenesis, and metastatic progression of cancer. After the oral administration, the effect of this capsule can be observed within 6 to 12 hours.
Indication
Kidney Cancer and Gastrointestinal Stromal Tumor
Side Effects
Sunitinib 50mg Capsule may cause some adverse impact on the body during the treatment, and most of them resolve on their own. Some common side effects include: Blurred vision
Cough
Nausea
Weakness
Rash
Fever
Abdominal pain
High blood pressure
Stomatitis
Back pain
Taste change
Weight loss
Indigestion
Bleeding gums
Thyroid imbalances
Loss of appetite
Constipation Contact a doctor immediately if you experience any serious or persistent side effects.
How To Use
Take this medicine as prescribed by your doctor. Sunitinib 50 mg Capsule may be taken with or without food, but it is better to take it at a fixed time every day to get effective results. Swallow the capsule as a whole with a glass of water and don't open, crush, or dissolve it.
Safety Advice
Alcohol
unsafe
Avoid the consumption of alcohol while taking Sunitinib 50 mg Capsule, as alcohol can reduce the effectiveness of the medicine and worsen the symptoms.
Pregnancy
consult your doctor
Pregnancy: Sunitinib 50 mg Capsule is not recommended during pregnancy as it is unsafe for the developing fetus.
Breast Feeding
consult your doctor
Breastfeeding women should discuss the potential risks and benefits of the Sunitinib 50 mg Capsule with their healthcare provider before starting treatment.
Driving
danger
Patients should avoid driving or operating machinery while taking this medicine if they experience side effects such as fatigue, dizziness, or blurred vision
Kidney
caution
Avoid the consumption of this medicine before consulting a doctor if you have any kidney-related issues.
Liver
caution
Avoid Sunitinib 50 mg Capsule consumption if you have any liver-related issues because this medicine causes liver toxicity, which can make your condition worse.
Missed Doses
It is advisable not to miss a dose. If you miss a scheduled dose of Sunitinib 50mg Capsule, contact your doctor immediately.
FAQs
Sunitinib 50 mg capsule is an anti-cancer medication, which is used in the treatment of Kidney cancer, pancreatic neuroendocrine tumors, and Gastrointestinal Stromal Tumors. This medication interferes with the growth of cancer cells and destroys
Some common side effects of sunitinib 50 mg capsule include fever, high blood pressure, loss of appetite, constipation, discoloration of the skin, tiredness, vomiting, etc.
While taking this medicine, you should avoid the consumption of grapefruit & grapefruit juice and breastfeeding.
Sunitinib capsule works by blocking the activity of tyrosine kinase inhibitors, which help to reduce the size of tumors and prevent them from multiplying.
Avoid driving while taking this medicine, as Sunitinib capsule can cause dizziness or affect your vision.
Reference
1. Chouhan, J. D., Zamarripa, D. E., Lai, P. H., Oramasionwu, C. U., & Grabinski, J. L. (2007). Sunitinib (Sutent®): A novel agent for the treatment of metastatic renal cell carcinoma. Journal of Oncology Pharmacy Practice, 13(1), 5-15.
2. Navid, F., Christensen, R., Minkin, P., Stewart, C. F., Furman, W. L., & Baker, S. (2008). Stability of sunitinib in oral suspension. Annals of Pharmacotherapy, 42(7-8), 962-966.
3. Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., ... & Casali, P. G. (2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. The Lancet, 368(9544), 1329-1338.
4.https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021938s13s17s18lbl.pdf
5. Blumenthal, G. M., Cortazar, P., Zhang, J. J., Tang, S., Sridhara, R., Murgo, A., ... & Pazdur, R. (2012). FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors. The oncologist, 17(8), 1108-1113.
Related Products
MARKETER DETAILS
Arechar HealthCare
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.